الفهرس 
Genetic DisordersOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
SUMMARY Rectal cancer is the third frequent diagnosed cancer and third cause of cancer death. Since 1990, it was universally accepted that curative intent surgery (TME) followed by chemoradiotherapy are the standard of care for patients with rectal cancer to reduce local recurrence and enhance overall survival.(Goldenberg et al., 2018) Neoadjuvant chemoradiation became the standard of care for rectal cancer after the 11 years follow up of the German CAO/ARO/AIO-94 study by (Sauer et al., 2012). Local recurrence frequently is associated with major morbidity including distal bowel and urinary obstruction, severe pain and diminished quality of life. (Goldenberg et al., 2018) This study aimed to evaluate tumor size as a prognostic factor for rectal adenocarcinoma local recurrence. This retrospective study included 100 patients who had rectal adenocarcinoma and were treated at Clinical Oncology and Nuclear Medicine department, Tanta University Hospital and Meet Ghmmr Oncology Center throughout the period of January 2015 to December 2017 with a follow up period of 5 years. During 5 years of follow up in our study, 12 patients (12%) had local recurrence. This was close to (Metwally et al., 2019) study with local recurrence 15.8% Patients with tumor size > 5 cm has a significantly shorter DFS. Disease free survival within 2-yrs for tumors ≤5 cm 96%, while 5-years DFS